Bio-Techne Co. (NASDAQ:TECH) Stock Holdings Increased by Simon Quick Advisors LLC

Simon Quick Advisors LLC grew its holdings in shares of Bio-Techne Co. (NASDAQ:TECH) by 11.9% in the fourth quarter, HoldingsChannel reports. The fund owned 4,560 shares of the biotechnology company’s stock after buying an additional 485 shares during the period. Simon Quick Advisors LLC’s holdings in Bio-Techne were worth $328,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Dimensional Fund Advisors LP grew its position in Bio-Techne by 9.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 894,352 shares of the biotechnology company’s stock valued at $64,082,000 after buying an additional 76,641 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in shares of Bio-Techne by 18.6% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 5,553 shares of the biotechnology company’s stock worth $398,000 after acquiring an additional 872 shares during the period. Canada Pension Plan Investment Board bought a new position in shares of Bio-Techne in the second quarter valued at approximately $172,000. Pacer Advisors Inc. increased its stake in shares of Bio-Techne by 42.1% during the second quarter. Pacer Advisors Inc. now owns 15,140 shares of the biotechnology company’s stock valued at $1,085,000 after acquiring an additional 4,488 shares during the period. Finally, Public Sector Pension Investment Board raised its holdings in Bio-Techne by 76.1% during the second quarter. Public Sector Pension Investment Board now owns 6,130 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 2,649 shares in the last quarter. Institutional investors own 98.95% of the company’s stock.

Bio-Techne Stock Performance

Shares of NASDAQ TECH opened at $76.91 on Friday. The stock’s fifty day simple moving average is $73.94 and its 200 day simple moving average is $74.46. The stock has a market capitalization of $12.22 billion, a price-to-earnings ratio of 81.82, a PEG ratio of 5.81 and a beta of 1.27. The company has a quick ratio of 3.26, a current ratio of 4.56 and a debt-to-equity ratio of 0.14. Bio-Techne Co. has a 52-week low of $61.16 and a 52-week high of $85.57.

Bio-Techne (NASDAQ:TECH) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.04. Bio-Techne had a return on equity of 12.76% and a net margin of 12.86%. The firm had revenue of $289.46 million for the quarter, compared to analysts’ expectations of $280.22 million. During the same quarter last year, the business posted $0.35 EPS. Bio-Techne’s revenue was up 4.5% on a year-over-year basis. As a group, sell-side analysts forecast that Bio-Techne Co. will post 1.68 earnings per share for the current fiscal year.

Bio-Techne Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, November 22nd. Investors of record on Monday, November 11th were given a $0.08 dividend. The ex-dividend date was Friday, November 8th. This represents a $0.32 annualized dividend and a dividend yield of 0.42%. Bio-Techne’s dividend payout ratio (DPR) is presently 34.04%.

Analyst Upgrades and Downgrades

TECH has been the subject of a number of research reports. StockNews.com raised Bio-Techne from a “hold” rating to a “buy” rating in a research note on Tuesday, November 12th. Scotiabank raised their target price on Bio-Techne from $83.00 to $88.00 and gave the company a “sector outperform” rating in a research note on Thursday, October 31st. Finally, Robert W. Baird boosted their price target on shares of Bio-Techne from $82.00 to $84.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $82.00.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.